MET and pancreatic neoplasm: In pancreatic cancer, c-MET was overexpressed up to 80% of pancreatic ductal adenocarcinoma cases, and c-MET alterations were shown to be a strong indicator for increased recurrence rates and overall poor survival for pancreatic ductal adenocarcinoma patient [8-11].